(Cure Lab, Inc.) One of the most pressing biomedical issues is the development of techniques that increase the efficiency of vaccines.

In a paper published on April 24, 2008 in the journal Vaccine, a Massachusetts biotechnology company, Cure Lab, Inc. has proposed a new technology for anti-viral and potentially anti-cancer vaccination.

Cure Lab demonstrates that deriving a vaccine antigen in two forms and then applying these two forms in combination elicits a much stronger immune response.